SCHEMBL1757600

SCHEMBL1757600

NNCc1ccc(F)cc1F

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.53
AGXT P21549 2/20 0.53
KDM4E B2RXH2 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.41
MAPK8 P45983 1/20 0.41
ACHE P22303 6/20 0.40
BCHE P06276 2/20 0.40
BACE1 P56817 2/20 0.40
ADRA2B P18089 1/20 0.39
P2RX7 Q99572 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15065821 0.98 IDO1 (0.55) IDO1AGXTKDM4ESMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL21332846 0.98 IDO1 (0.55) IDO1AGXTKDM4ESMN1; SMN2ALDH1A1
SCHEMBL23159231 0.83 DPP4 (0.42) IDO1AGXTALDH1A1GAAMAPK8
Hydrochloric Acid SCHEMBL15065772 0.81 ALDH1A1 (0.44) IDO1AGXTALDH1A1GAAMAPK8
SCHEMBL25588073 0.80 IDO1 (0.50) IDO1AGXTKDM4ESMN1; SMN2ALDH1A1
SCHEMBL11158402 0.79 KDM1A (0.48) P2RX7
SCHEMBL15076829 0.79 CXCR3 (0.43) ALDH1A1
SCHEMBL23134838 0.79 P2RX7 (0.43) IDO1AGXTKDM4EALDH1A1GAA
SCHEMBL31351643 0.79 P2RX7 (0.41) IDO1AGXTALDH1A1GAAP2RX7
SCHEMBL11621445 0.79 P2RX7 (0.43) KDM4EALDH1A1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025011546-A1 HUMAN CASEINOLYTIC PROTEASE P AGONISTS AND USES THEREOF ACELON THERAPEUTICS (CN) 2025-01-16 WO disclosed
US-20240294523-A1 HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2024-09-05 US disclosed
WO-2022258052-A1 HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF 劲方医药科技(上海)有限公司 2022-12-15 WO disclosed
WO-2022258052-A1 HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF 劲方医药科技(上海)有限公司 2022-12-15 WO disclosed
US-20210214364-A1 sGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2021-07-15 US disclosed
EP-3092231-B1 SGC STIMULATORS IRONWOOD PHARMACEUTICALS INC (US) 2018-06-27 EP disclosed
US-9598410-B2 Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridines, their use as medicament, and pharmaceutical preparations comprising them SANOFI (FR) 2017-03-21 US disclosed
US-20160311826-A1 SGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2016-10-27 US disclosed
US-20160311826-A1 SGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2016-10-27 US disclosed
CN-103930421-B 4,5,6,7-tetrahydrochysene-1H-pyrazolo [4,3-c] pyridine that replaces, they are as the purposes of medicine and the pharmaceutical preparation that comprises them 赛诺菲 2016-06-29 CN disclosed
CN-104066731-A 2-benzyl, 3- (pyrimidin-2-yl) substituted pyrazoles useful as SGC stimulators IRONWOOD PHARMACEUTICALS INC 2014-09-24 CN disclosed
EP-2755973-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI (FR) 2014-07-23 EP disclosed
WO-2013096744-A1 HEPATITIS B ANTIVIRAL AGENTS NOVIRA THERAPEUTICS, INC. (US) 2013-06-27 WO disclosed
WO-2013037415-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI (FR) 2013-03-21 WO disclosed
WO-2013037914-A1 SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI (FR) 2013-03-21 WO disclosed
WO-2011055270-A1 INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS WYETH LLC (US) 2011-05-12 WO disclosed
WO-2011055270-A1 INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS WYETH LLC (US) 2011-05-12 WO disclosed
US-20110105509-A1 INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS WYETH, LLC (US) 2011-05-05 US disclosed
US-20110105509-A1 INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS WYETH, LLC (US) 2011-05-05 US disclosed
US-20110105509-A1 INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS WYETH, LLC (US) 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294523-A1 HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF RIPK1, RIPK4, RIPK3 IDO1 2537/4885AGXT 3180/4885KDM4E 3107/4885
US-20160311826-A1 SGC STIMULATORS GUCY1A1, GUCY1B1, GUCY1A2 IDO1 4366/4885AGXT 2752/4885KDM4E 1072/4885
US-20210214364-A1 sGC STIMULATORS GUCY1B1, GUCY1A1, GUCY1B2 IDO1 4543/4885AGXT 3447/4885KDM4E 871/4885
US-20110105509-A1 INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS HRH2, CRHR2, CRHR1 IDO1 154/4885AGXT 2866/4885KDM4E 4693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.